8-K: Starling Oncology Reports Strong Q3 Results, Eyes Profitability

Starling Oncology announced robust third-quarter results, with revenue up 24% year-over-year to $170 million, and a positive Adjusted EBITDA of $3.4 million, signaling a strong trajectory towards sustained profitability.

Summary

• Starling Oncology reported a 24% year-over-year increase in total revenue for the third quarter of 2026, reaching $170 million.
• The company achieved a positive Adjusted EBITDA of $3.4 million in Q3 2026, marking its second consecutive quarter of positive EBITDA.
• Specialty pharmacy revenue grew by 44% year-over-year to $109 million, with a gross margin of 24%.
• The Medical Loss Ratio (MLR) improved to 81%, a decrease of 400 basis points sequentially.
• The company reiterated its FY2026 revenue guidance of $650-$660 million and projects Adjusted EBITDA between $4-$6 million.
• Starling Oncology is on track to achieve positive Adjusted EBITDA in 2026, driven by scale, cost discipline, and an improving payer mix.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, indicating strong operational execution and a clear path towards profitability, supported by strategic refinancing and robust revenue growth.

Positives

• Revenue growth of 24% year-over-year to $170 million in Q3 2026.
• Achieved positive Adjusted EBITDA of $3.4 million in Q3 2026, second consecutive quarter.
• Specialty pharmacy revenue increased by 44% year-over-year to $109 million with a 24% gross margin.
• Medical Loss Ratio (MLR) improved to 81%, down 400 basis points sequentially.
• Successful refinancing of $86 million Deerfield note with OrbiMed, strengthening the balance sheet and expanding revolver capacity.
• Launched Starling Oncology Nexus to enhance provider engagement and clinical pathway adherence.
• Strong projected FY2026 revenue guidance of $650-$660 million.
• Projected positive Adjusted EBITDA of $4-$6 million for FY2026.

Negatives

• The Medical Loss Ratio (MLR) is expected to be in the 85-90% range over the next 12 months as delegated lives ramp, before normalizing to 75-85% at run-rate.
• While Adjusted EBITDA is positive, the company reported a negative Adjusted EBITDA of ($12.4) million for FY2025 and ($25.8) million for FY2024.

Risks

• Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from projections.
• The company's reliance on capitation and fee-for-service models may be subject to changes in payer mix and reimbursement rates.
• The oncology drug market is subject to significant cost inflation and evolving treatment landscapes.
• The success of the Starling Oncology Nexus platform in driving adherence and efficiency is subject to adoption and effectiveness.

Future Outlook

The company projects FY2026 revenue between $650-$660 million and Adjusted EBITDA between $4-$6 million. Long-term targets include approximately 20% revenue CAGR through 2028, with capitation and dispensary making up roughly 30% and 50% of total revenue, respectively, and Adjusted EBITDA margins scaling to mid-single digits of revenue.

Management Comments

• The company is on track for positive Adjusted EBITDA in 2026, driven by scale, cost discipline, and an improving payer mix.
• Specialty pharmacy revenue of $109M increased 44% YoY with a gross margin of 24%.
• MLR declined 400bps to 81% QoQ.
• Ramping Nexus provider portal to deepen provider engagement.

Industry Context

StockSavvy.ai notes that Starling Oncology's focus on value-based care (VBC) in oncology aligns with a significant industry trend driven by rising cancer care costs and the desire for more efficient, patient-centric models. The company's diversified revenue streams and integrated platform position it to capitalize on the shift away from traditional fee-for-service models.

Comparison to Industry Standards

• Starling Oncology's Q3 2026 MLR of 81% is noted as a decrease of 400 basis points sequentially, indicating improved cost management.
• The company's specialty pharmacy gross margin of 24% is a key driver of its financial performance.
• The projected FY2026 Adjusted EBITDA of $4-$6 million indicates a move towards profitability, contrasting with negative EBITDA in prior years.
• The company aims for mid-single-digit Adjusted EBITDA margins by 2028, a common target for mature VBC platforms.

Stakeholder Impact

• Shareholders: Positive outlook with a clear path to profitability and projected revenue growth, supported by a strengthened balance sheet.
• Payors: Potential for cost savings through value-based care models and improved MLR.
• Providers: Enhanced engagement and clinical pathway adherence through the Starling Oncology Nexus platform.
• Patients: Access to community-based oncology care, integrated services, and potentially improved satisfaction and outcomes.

Next Steps

• Continue to ramp the Nexus provider portal to deepen provider engagement.
• Focus on achieving positive Adjusted EBITDA in 2026.
• Execute on long-term growth targets, including revenue growth and margin expansion through 2028.
• Expand capitation and dispensary revenue mix towards target percentages.

Key Dates

Recommendation

The company is demonstrating strong operational execution with significant revenue growth and a clear path to profitability, as evidenced by positive EBITDA in the last two quarters and strong guidance. However, the historical negative EBITDA, the expected near-term MLR increase, and the inherent risks in the healthcare sector warrant a 'hold' rating until sustained profitability and margin expansion are more firmly established.

Keywords

Oncology, Value-Based Care, Specialty Pharmacy, Capitation, EBITDA, Revenue Growth, Healthcare, Managed Care